Panavir suppositories, 0.2 mg, 5 pcs.

Active substance:

 Panavir® (Solanum tuberosum shoot polysaccharides) 200 mcg;

Excipients:

confectionery fat or solid fat - 1.0198 g;

paraffin - 0.09 g;

emulsifier T-2 - 0.09 g;

Panavir® - purified extract of the shoots of the plant Solanum tuberosum; the main active ingredient is hexose glycoside, consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, uronic acids.

Panavir® is an antiviral and immunomodulating agent. It increases the nonspecific resistance of the body to various infections and promotes the induction of interferons alpha and gamma by white blood cells.

In therapeutic doses, the drug is well tolerated.

Tests have shown the absence of mutagenic, teratogenic, carcinogenic, allergenic and embryotoxic effects. In preclinical studies in laboratory animals, a negative effect on the reproductive function and development of the fetus has not been established.

It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in the pseudo-allergic inflammatory reaction test for concanavalin A.

An analgesic effect is shown on models of neurogenic pain and pain caused by the inflammatory process and thermal irritation.

It has an antipyretic effect.

The model of parkinsonism syndrome caused by systemic administration of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine shows neuroprotective properties.

It has the ability to improve the functions of the retina and optic nerve.

It has wound healing properties in the conditions of a model of gastric ulcer.

• herpes virus infections of various localization, including recurrent genital herpes, herpes zoster and ophthalmic herpes;
• secondary immunodeficiency conditions against the background of infectious diseases;
• cytomegalovirus infection, including in patients with habitual miscarriage. It is used in women with a chronic viral infection and interferon-deficient state in preparation for pregnancy;
• papillomavirus infection (anogenital warts) - as part of complex therapy;
• tick-borne encephalitis - in order to reduce viral load and relieve neurological symptoms (anisoreflexia, decreased reflexes, soreness of exit points of cranial nerves, nystagmus) - as part of complex therapy;
• SARS and influenza - as part of complex therapy.

If it is necessary to use the drug during lactation, breastfeeding should be discontinued while the drug is being used.

• hypersensitivity;
• pregnancy;
• lactation period;
• childhood.

The drug is well tolerated, possible complications may be associated with individual intolerance and increased sensitivity to the components of the drug.

Rectally. For the treatment of herpesvirus infections and tick-borne encephalitis, 1 suppository is used twice with an interval of 48 or 24 hours. If necessary, the treatment can be repeated after 1 month.

For the treatment of cytomegalovirus and papillomavirus infections, 1 suppository is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

For the treatment of acute respiratory viral infections and influenza, 1 suppository is used with an interval of 24 hours for 5 days.

Intravaginally. Vaginal suppositories are inserted into the vagina in the evening, as deep as possible, in a supine position with slightly bent legs, 1 vaginal suppository daily for 5 days. A repeated course of treatment is possible after consulting a doctor.

simultaneous treatment of sexual partners is necessary to prevent urogenital reinfection. If there is no effect, the diagnosis should be confirmed.

rectal suppositories